Advertisement
Original Research Article| Volume 104, ISSUE 4, P426-431, October 2021

Acceptance of HPV vaccination at the abortion visit at a clinic in New York City in 2017 to 2018

      Abstract

      Objectives

      Human Papillomavirus vaccination remains a public health concern. Our primary objective was to examine whether eligible people, in an underimmunized population, seeking abortion find the abortion visit an acceptable opportunity to receive the Human Papillomavirus (HPV) vaccine. Our secondary objectives include comparing vaccine acceptors to vaccine decliners on knowledge and attitudinal factors related to the HPV vaccine.

      Study Design

      We conducted a cross sectional study in which we offered free HPV vaccine series initiation and completion to eligible patients presenting for abortion services at an outpatient health center. We administered surveys to both vaccine acceptors and decliners, to assess utilization of health services, knowledge of the HPV vaccine, and reasons for not having initiated or completed the vaccine series previously.

      Results

      101 study participants were offered HPV vaccination; 50 participants accepted and 51 participants declined. All participants completed the survey. Seven of fifty vaccine acceptors completed the vaccine series. Vaccine acceptance was associated with new knowledge that HPV causes cervical cancer. (acceptors = 72.0%, decliners = 52.9%, p = 0.05) The most common reason among both groups for not previously initiating the vaccine was “No one offered it to me” (acceptors = 58.0%, decliners = 53.5%, p = 0.46). A considerable number of participants had not previously heard of the HPV vaccine, 44% of those who accepted, and 35.3% of those who declined (p = 0.64) vaccination at the time of their abortion.

      Conclusion

      The abortion visit offers an important opportunity to start or to finish the HPV vaccine series. Most patients are receptive to receiving additional services and were never previously offered the HPV vaccine. Practices and policies aimed at utilizing missed opportunities for HPV vaccine catch up can increase HPV vaccine prevalence among young adult women to reduce lifetime risk for cervical cancer.

      Implications

      The abortion visit may be an opportunity for HPV vaccination catch up in an underimmunized population. Abortion providers may consider offering patients other preventive health care services.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • U.S. Department of Health and Human Services
        Immunization and infectious diseases.
        Healthy People. 2014;
        • Center for Disease Control and Prevention (CDC)
        Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013—United States.
        MMWR Morb Mortal Wkly Rep. 2013; 62: 591-595
        • Elam-Evans LD
        • Yankey D
        • Singleton JA
        • Sterrett N
        • Markowitz L
        • Williams CL
        • et al.
        National, regional, state and selected local area vaccination coverage among adolescents aged 13-17 years - United states, 2019.
        MMWR Morb Mortal Wkly Rep. 2020; 69: 1109-1116
        • Walker TY
        • Elam-Evans LD
        • Singleton JA
        • Yankey D
        • Markowitz LE
        • Fredua B
        • et al.
        National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United states, 2016.
        MMWR Morb Mortal Wkly Rep. 2017; 66: 874-882
        • Meties E
        • Szilagyi PG
        • Chesson HW
        • Unger ER
        • Romero JR
        • Markowitz LE
        Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices.
        MMWR Morb Mortal Wkly Rep. 2019; 68: 698-702
        • Oliver SE
        • Unger ER
        • Lewis R
        • McDaniel D
        • Gargano JW
        • Steinau M
        • et al.
        Prevalence of human papillomavirus among females after vaccine introduction-national health and nutrition examination survey, United states, 2003-2014.
        J Infect Dis. 2017; 216: 594-603
        • Rodriguez AC
        • Solomon D
        • Herrero R
        • Hildesheim A
        • Gonzalez P
        • Wacholder S
        • et al.
        Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment.
        Am J Epidemiol. 2013; 178: 752-760
        • Jones RK
        • Jerman J
        Population group abortion rates and lifetime incidence of abortion: United states, 2008-2014.
        Am J Public Health. 2017; 107: 1904-1909
        • Lau JS
        • Adams SH
        • Park MJ
        • Boscardin WJ
        • Irwin CE
        Improvement in preventive care of young adults after the affordable care act: the affordable care act is helping.
        JAMA Pediatr. 2014; 168: 1101-1106https://doi.org/10.1001/jamapediatrics.2014.1691
        • Luquis RR
        • Kensinger WS
        Perceptions of health care and access to preventive services among young adults.
        J Community Health. 2017; 42: 1204-1212
        • Richards MJ
        • Peters M
        • Sheeder J
        Human papillomavirus vaccine: continuation, completion, and missed opportunities.
        J Pediatr Adolesc Gynecol. 2016; 29: 117-121
        • Oliveira CR
        • Rock RM
        • Shapiro ED
        • Xu X
        • Lundsberg L
        • Zhang LB
        • et al.
        Missed opportunities for HPV immunization among young adult women.
        Am J Obstet Gynecol. 2018; 218: 326.e1-326.e7
        • O'Connell K
        • Jones HE
        • Simon M
        • Saporta V
        • Paul M
        • Lichtenberg ES
        • et al.
        First-trimester surgical abortion practices: a survey of National Abortion Federation members.
        Contraception. 2009; 79: 385-392
        • Walling EB
        • Benzoni N
        • Dornfeld J
        • Bhandari R
        • Sisk BA
        • Garbutt J
        • et al.
        Interventions to improve HPV vaccine uptake: a systematic review.
        Pediatrics. 2016; 138 (e20153863)
        • Berenson AB
        • Rahman M
        • Hirth JM
        • Rupp RE
        • Sarpong KO
        A human papillomavirus vaccination program for low-income postpartum women.
        Am J Obstet Gynecol. 2016; 215: 318.e1-318.e9
        • Cory L
        • Cha B
        • Ellenberg S
        • Bogner HR
        • Hwang WT
        • Smith JS
        • et al.
        Effects of educational interventions on human papillomavirus vaccine acceptability: a randomized controlled trial.
        Obstet Gynecol. 2019; 134: 376-384
        • Reiter PL
        • Stubbs B
        • Panozzo CA
        • Whitesell D
        • Brewer NT
        HPV and HPV vaccine education intervention: effects on parents, healthcare staff, and school staff.
        Cancer Epidemiol Biomarkers Prev. 2011; 20: 2354-2361
        • Moss JL
        • Reiter PL
        • Rimer BK
        • Brewer NT
        Collaborative patient-provider communication and uptake of adolescent vaccines.
        Soc Sci Med. 2016; 159: 100-107
        • Brewer NT
        • Fazekas KI
        Predictors of HPV vaccine acceptability: a theory-informed, systematic review.
        Prev Med. 2007; 45: 107-114
        • Simons HR
        • Unger ZD
        • Lopez PM
        • Kohn JE
        Predictors of human papillomavirus vaccine completion among female and male vaccine initiators in family planning centers.
        Am J Public Health. 2015; 105: 2541-2548
        • Sankaranarayanan R
        • Prabhu PR
        • Pawlita M
        • Gheit T
        • Bhatla N
        • Muwonge R
        • et al.
        Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
        Lancet Oncol. 2016; 17: 67-77
        • Berenson AB
        • Hirth JM
        • Chang M
        Change in human papillomavirus prevalence among U.S. women aged 18-59 years, 2009-2014.
        Obstet Gynecol. 2017; 130: 693-701
        • Mehanna H
        • Bryant TS
        • Babrah J
        • Louie K
        • Bryant JL
        • Spruce RJ
        • et al.
        Human papillomavirus (HPV) vaccine effectiveness and potential herd immunity for reducing oncogenic oropharyngeal HPV-16 prevalence in the United kingdom: a cross-sectional study.
        Clin Infect Dis. 2019; 69: 1296-1302
        • Sonawane K
        • Nyitray AG
        • Nemutlu GS
        • Swartz MD
        • Chhatwal J
        • Deshmukh AA
        Prevalence of human papillomavirus infection by number of vaccine doses among US women.
        JAMA Netw Open. 2019; 2e1918571
        • Newmann SJ
        • Dufour MS
        • McFarland W
        • Oderman L
        • Kellogg T
        • Louie B
        • et al.
        HIV voluntary counseling and testing at an abortion clinic: missed opportunities for diagnosis.
        Contraception. 2013; 88: 147-152
        • Matulich M
        • Cansino C
        • Culwell KR
        • Creinin MD
        Understanding women's desires for contraceptive counseling at the time of first-trimester surgical abortion.
        Contraception. 2014; 89: 36-41
        • Kavanaugh ML
        • Carlin EE
        • Jones RK
        Patients' attitudes and experiences related to receiving contraception during abortion care.
        Contraception. 2011; 84: 585-593
      1. Guttmacher Institute. Medicaid funding of abortion. Accessed at: 16 February. 2018, www.guttmacher.org/evidence-you-can-use/medicaid-funding-abortion.

      2. The HPV vaccine: access and use in the U.S.” The henry J. kaiser family foundation, The Henry J. Kaiser family foundation. Accessed at: October19, 2017, www.kff.org/womens-health-policy/fact-sheet/the-hpv-vaccine-access-and-use-in/.

        • Meites E
        • Szilagyi PG
        • Chesson HW
        • Unger ER
        • Romero JR
        • Markowitz LE
        Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices.
        MMWR Morb Mortal Wkly Rep. 2019; 68: 698-702https://doi.org/10.15585/mmwr.mm6832a3
      3. Human Papillomavirus Vaccination: ACOG Committee Opinion Summary, Number 809.
        Obstet Gynecol. 2020; 136: 435-436